Harvard Bioscience and Etisense entered into an agreement to offer DECRO, Etisense’s non-invasive telemetry jacket and associated physiological monitoring software, to a broad range of pre-clinical customers in the North American and European markets. Harvard Bioscience’s Data Sciences International pre-clinical business will serve as the exclusive distributor of Etisense’s line of DECRO telemetry jackets and software in North America, the United Kingdom, and Ireland. Etisense will also supply a dedicated version of its DECRO telemetry jackets to be marketed by DSI in North America and Europe. These telemetry jackets, which will expand DSI’s Jacketed External Telemetry product line, will be specially adapted to integrate with DSI’s Ponemah monitoring and data management software.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HBIO:
- Harvard Bioscience and Etisense Announce Agreement for Supply and Distribution of DECRO Miniature Telemetry Jacket Platform for Pre-Clinical Research
- Harvard Bioscience management to meet with Benchmark
- Harvard Bioscience sees FY23 revenue $116M-$120M, consensus $120.76M
- Harvard Bioscience reports Q2 adjusted EPS 4c, consensus 6c
- Harvard Bioscience Announces Second Quarter 2023 Financial Results